Abstract
The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.
Original language | English |
---|---|
Journal | Nature Medicine |
Early online date | 19 Apr 2024 |
DOIs |
|
State | E-pub ahead of print - 19 Apr 2024 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© Springer Nature America, Inc. 2024.
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology